Erchonia's body-contouring laser wins 510(k) clearance; Everist Genomics trial shows test predicts colon cancer recurrence;

 @MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

> Erchonia has obtained 510(k) clearance for its Zerona body-contouring laser, designed to reduce fat around the arms. Release

> Arteriocyte Medical Systems gained FDA approval to make and distribute an anticoagulant solution for use with its 510(k)-cleared Magellan platelet separation system. Release

> Exosome Diagnostics has inked a deal with Life Technologies to use Applied Biosystems' tech for its exosome biofluid in vitro diagnostics cancer oncology program. Release

> N-of-One, a Massachusetts company that offers diagnostic and treatment strategy roadmaps for personalized cancer care, has appointed Christine Cournoyer as its new CEO. She is a former president and CEO of the health information software company Picis. Release

> Everist Genomics has generated promising results from an international validation study that showed its OncoDefender-CRC colorectal cancer test helped predict recurrence in node-negative invasive colorectal cancer patients. Release

Biotech News

 @FierceBiotech: Look out, Roche: GlaxoSmithKline aces pivotal studies for pair of melanoma drugs. Story | Follow @FierceBiotech

 @JohnCFierce: Updated my ASCO roundup story with regorafenib and Aveo study. More | Follow @JohnCFierce

 @RyanMFierce: My report on 5 next-gen software tools for biopharma R&D. Report | Follow @RyanMFierce

> Boehringer sights AZ and Roche drugs in targeted lung cancer fight. Article

> Ariad's ponatinib scores well in key leukemia study. More

> Sources: AstraZeneca, Bristol make bids for Amylin. Story

> T-DM1 results push Genentech's armed antibody tech into ASCO's center stage. News

Pharma News

 @FiercePharma: Some non-ASCO news: If Greece leaves euro, drug pricing across EU would get even worse, EFPIA says--BloombergArticle | Follow @FiercePharma

> J&J should split itself three ways, Goldman analyst says. More

> Study of Treanda shows great promise for Teva's drug. News

> ASCO: Data on J&J, Medivation meds spell trouble for Provenge. Story

Biotech IT News

> Proteins computer-designed to block flu invasions. Story

> Accelrys software to support efforts in Texas to study rare cancers. Article

> NIH group to award up to $20B in IT contracts. More

> Dotmatics starts up mobile strategy with iPad app. News

And Finally... Novacure is now seeking expanded FDA approval to use its tumor targeting field cancer therapy system beyond use for some brain cancers to also treat non-small cell lung cancer. The company's technology relies on non-invasive electromagnetic therapy. Story

Suggested Articles

Testing company LumiraDx is selling its pandemic virus rapid test across the U.K. targeting individuals without any COVID-19 symptoms.

The FDA has given genomics firm Helix a wider emergency use authorization for its pandemic test.

Celltrion has nabbed a speedy preapproval for its quick pandemic virus test as it forecasts high demand.